References
- MillerAJMihmMCJrMelanomaN Engl J Med20063551516516822996
- International Agency for Research on CancerThe GLOBOCAN project [homepage on the Internet]Geneva, SwitzerlandWorld Health Organization2010 Available from: http://globocan.iarc.frAccessed January 12, 2013
- National Cancer InstituteSEER stat fact sheets: melanoma of the skin [webpage on the Internet]Bethesda, MDNational Cancer Institute Available from: http://seer.cancer.gov/statfacts/html/melan.htmlAccessed January 12, 2013
- KornELLiuPYLeeSJMeta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trialsJ Clin Oncol200826452753418235113
- National Cancer InstituteMelanoma treatment (PDQ) [webpage on the Internet]Bethesda, MDNational Cancer Institute52013 Available from: http://www.cancer.gov/cancertopics/pdq/treatment/melanoma/HealthProfessional/page4Accessed on August 26, 2013
- American Cancer SocietyDetailed guide on treatment of melanoma by stage Available at: http://www.cancer.org/cancer/skin-cancer-melanoma/detailedguide/melanoma-skin-cancer-treating-by-stageAccessed August 26, 2013
- FrickerJNew era in metastatic melanomaMol Oncol2010419197
- QuirbtIVermaSPetrellaTBakKCharetteMfor Members of the Melanoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based CareTemozolomide for the treatment of metastatic melanomaCurr Oncol2007141273317576461
- AgarwalaSSCurrent systemic therapy for metastatic melanomaExpert Rev Anticancer Ther20099558759519445576
- PatelPMSuciuSMortierLfor EORTC Melanoma GroupExtended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)Eur J Cancer201147101476148321600759
- AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol19991772105211610561265
- HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
- RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
- BrunetJFDenizotFLucianiMFA new member of the immunoglobulin superfamily – CTLA-4Nature198732861272672703496540
- KormanAJPeggsKSAllisonJPCheckpoint blockade in cancer immunotherapyAdv Immunol20069029733916730267
- van ElsasAHurwitzAAAllisonJPCombination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentationJ Exp Med1999190335536610430624
- KirkwoodJMTarhiniAAPanelliMCNext generation of immunotherapy for melanomaJ Clin Oncol200826203445345518612161
- HurwitzAAFosterBAKwonEDCombination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockadeCancer Res20006092444244810811122
- ParadisTJFloydEBurkwitJThe anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gammaCancer Immunol Immunother200150312513311419179
- GrazianiGTentoriLNavarraPIpilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancerPharmacol Res201265192221930211
- Bristol-Myers Squibb CompanyIpilimumab US Prescribing Information 2011Princeton, NJBristol-Myers Squibb Company2012 Available from: http://packageinserts.bms.com/pi/pi_yervoy.pdfAccessed on January 12, 2013
- YERVOY 5 mg/mL concentrate for solution for infusion – Summary of Product Characteristics (SPC) [webpage on the Internet]Electronic Medicines Compendium2013 Available from: http://www.medicines.org.uk/emc/medicine/24779Accessed on January 12, 2013
- WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
- O’DaySJMaioMChiarion-SileniVEfficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnn Oncol20102181712171720147741
- Di GiacomoAMAsciertoPAPillaLIpilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialLancet Oncol201213987988622894884
- PatelSPHwuWJKimKBPhase II study of the frontline combination of ipilimumab and temozolamide in patients with metastatic melanoma [abstract]J Clin Oncol2012Suppl8514
- PrietoPAYangJCSherryRMCTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaClin Cancer Res20121872039204722271879
- MakerAVPhanGQAttiaPTumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II studyAnn Surg Oncol200512121005101616283570
- BernardoSGMoskalenkoMPanMElevated rates of transaminitis during ipilimumab therapy for metastatic melanomaMelanoma Res2013231475423262440
- HamidOSchmidtHNissanAA prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJ Transl Med2011920422123319
- RosenbergSAYangJCRestifoNPCancer immunotherapy: moving beyond current vaccinesNat Med200410990991515340416
- SchwartzentruberDJLawsonDHRichardsJMgp100 peptide vaccine and interleukin-2 in patients with advanced melanomaN Engl J Med2011364222119212721631324
- RetsasSLatest developments in the treatment of melanoma: ‘a penicillin moment for cancer’?J R Soc Med2011104626927221659402
- MargolinKIpilimumab in a Phase II trial of melanoma patients with brain metastasesOncoimmunology2012171197119923170278
- FonkemEUhlmannEJFloydSRMelanoma brain metastasis: overview of current management and emerging targeted therapiesExpert Rev Neurother201212101207121523082737
- MargolinKErnstoffMSHamidOIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialLancet Oncol201213545946522456429
- WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
- KhattakMAFisherRHughesPGoreMLarkinJIpilimumab activity in advanced uveal melanomaMelanoma Res2013231798123211837
- KhanKDCallahanMPostowMAEfficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations [abstract]J Clin Oncol2012Suppl8511
- DanielliRRidolfiRChiarion-SileniVIpilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacyCancer Immunol Immunother2012611414821833591
- CulverMEGatesmanMLManclEELoweDKIpilimumab: a novel treatment for metastatic melanomaAnn Pharmacother201145451051921505108
- TivolEABorrielloFSchweitzerANLynchWPBluestoneJASharpeAHLoss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity1995355415477584144
- WeberJSKählerKCHauschildAManagement of immune-related adverse events and kinetics of response with ipilimumabJ Clin Oncol201230212691269722614989
- Bristol-Myers SquibbIpilimumab US prescribing information: risk evaluation and mitigation strategy [webpage on the Internet]Princeton, NJBristol-Meyers Squibb2012 Available from: http://www.yervoy.com/hcp/rems.aspxAccessed January 12, 2013
- TrinhVAHagenBIpilimumab for advanced melanoma: A pharmacologic perspectiveJ Oncol Pharm Pract Epub10112012
- WeberJThompsonJAHamidOA randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaClin Cancer Res200915175591559819671877
- Gaudy-MarquesteCMonestierSFranquesJCantaisERichardMAGrobJJA severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitisJ Immunother2013361777823211620
- AminADePrilVHamidOEvaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity [abstract]J Clin Oncol200927Suppl 159037
- PhanGQYangJCSherryRMCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProc Natl Acad Sci U S A2003100148372837712826605
- JohnstonRLLutzkyJChodhryABarkinJSCytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximabDig Dis Sci200954112538254019104936
- YangJCHughesMKammulaUIpilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitisJ Immunother200730882583018049334
- LynchTJBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyJ Clin Oncol201230172046205422547592
- ReckMBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnn Oncol2013241758322858559
- KantoffPWHiganoCSShoreNDfor IMPACT Study InvestigatorsSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
- SmallEJTchekmedyianNSRiniBIFongLLowyIAllisonJPA pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerClin Cancer Res20071361810181517363537
- van den EertweghAJVersluisJvan den BergHPCombined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialLancet Oncol201213550951722326922
- MadanRAMohebtashMArlenPMIpilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialLancet Oncol201213550150822326924
- RoyalRELevyCTurnerKPhase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinomaJ Immunother201033882883320842054
- AnsellSMHurvitzSAKoenigPAPhase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphomaClin Cancer Res200915206446645319808874
- HodiFSMihmMCSoifferRJBiologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsProc Natl Acad Sci U S A200310084712471712682289
- CornishDHolterhuesCvan de Poll-FranseLVCoeberghJWNijstenTA systematic review of health-related quality of life in cutaneous melanomaAnn Oncol200920Suppl 6vi51vi5819617298
- TraskPCPatersonAGEsperPPauJRedmanBLongitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferonPsychooncology200413852653615295774
- BoyleDAPsychological adjustment to the melanoma experienceSemin Oncol Nurs2003191707712638383
- CohenLParkerPASternerJDe MoorCQuality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumor-derived vaccineMelanoma Res200212550551112394193
- SpecenierPIpilimumab in melanomaExpert Rev Anticancer Ther201212121511112123181437
- NICE guideline: Melanoma (stage III or IV)- Ipilimumab: guidance [webpage on the Internet] Available from: http://guidance.nice.org.uk/TA268/Guidance/pdf/EnglishAccessed November 21, 2013
- QuezadaSAPeggsKSCurranMAAllisonJPCTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsJ Clin Invest200611671935194516778987
- LiakouCIKamatATangDNCTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patientsProc Natl Acad Sci U S A200810539149871499218818309
- FuTHeQSharmaPThe ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapyCancer Res201171165445545421708958
- Di GiacomoAMCalabròLDanielliRLong-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programmeCancer Immunol Immunother Epub4172013